openheart.bmj2d
Global, regional and national burdens of cardiovascular disease attributable to secondhand smoke from 1990–2019: an age-period-cohort analysis
Background Over the past three decades, significant disparities in the global burden of cardiovascular disease (CVD) have ...
openheart.bmj2d
Phase 1 study of novel anti-platelet agent to overcome pharmacogenomic limitations of clopidogrel
Aims Clopidogrel is the most commonly prescribed thienopyridine as part of dual anti-platelet therapy for the treatment of ...
openheart.bmj2d
Association of blood pressure and left ventricular mass with subclinical coronary atherosclerosis
Background Left ventricular (LV) mass is closely associated with atherosclerotic heart disease, but the mechanisms are not well defined. This study aimed to evaluate the risk factors associated with ...
openheart.bmj3d
Discrimination and calibration performances of non-laboratory-based and laboratory-based cardiovascular risk predictions: a systematic review
Background and objective This review compares non-laboratory-based and laboratory-based cardiovascular disease (CVD) risk prediction equations in populations targeted for primary prevention. Design ...
openheart.bmj3d
Revealing the limitations of 10-year MACE observations: 20-year observed total cardiovascular burden in the EPIC-Norfolk study
Background Primary prevention strategies for cardiovascular disease (CVD) conventionally rely on 10-year risk estimates of major adverse cardiovascular events (MACE). However, communicating ...
openheart.bmj2d
Efficacy and safety of anti-thrombotic therapy after surgical mitral valve repair: a scoping review
Background Mitral valve repair (MVr) is the gold standard treatment for degenerative mitral regurgitation, yet there is ongoing controversy regarding optimal anti-thrombotic therapy post-MVr. This ...